Better Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTTX research report →
Companywww.bettertx.com
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes.
- CEO
- David Perry
- IPO
- 2021
- Employees
- 54
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $5.45K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -221.99%
- ROIC
- -273.67%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-39,760,000 · 1.43%
- EPS
- $-1.69 · 1.17%
- Op Income
- $-38,262,000
- FCF YoY
- 5.58%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.69
- Avg Volume
- 3.59K
Get TickerSpark's AI analysis on BTTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 24 | PERRY DAVID P | other | 839,895 |
| Jan 9, 24 | PERRY DAVID P | other | 1,471,453 |
| Dec 18, 23 | PERRY DAVID P | other | 3,750 |
| Dec 18, 23 | Carmona Richard H | other | 3,750 |
| Dec 18, 23 | LAVIZZO-MOUREY RISA J | other | 3,750 |
| Dec 18, 23 | Wynholds Kristin | other | 25,362 |
| Dec 18, 23 | Parker Geoffrey M. | other | 3,750 |
| Dec 18, 23 | Armanino Andrew J. | other | 3,750 |
| Dec 18, 23 | Miller Leslie A. | other | 3,587 |
| Dec 18, 23 | Granger Elder | other | 3,750 |
Our BTTX Coverage
We haven't published any research on BTTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BTTX Report →